Marex Group plc acquires Levmet
By:
Marex Group plc via
GlobeNewswire
June 01, 2026 at 07:00 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, today announces it has acquired Levmet, further expanding its physical market making operations and adding capabilities in European power and gas trading. Headquartered in Monaco, Levmet is a liquidity provider in both physical and derivatives markets across base metals, ferrous metals, energy and power. Acquiring Levmet adds new capabilities to Marex with which it can serve its clients and the broader commodity ecosystem, consistent with its strategy to diversify earnings. Simon van den Born, Marex President commented: “The acquisition of Levmet is consistent with our strategy to add capabilities to further diversify our service offering. This is an exciting addition for Marex and we see significant opportunities to leverage Levmet’s relationships and capabilities. It is a well-run business with a robust focus on risk management.” Andrew Campbell, CEO of Levmet, commented: “We are excited to join Marex’s global platform. Their dynamic culture, combined with the breadth and depth of their capabilities will give our team more ways to enhance our service and support the continued growth of the business. We look forward to the opportunities this creates for our counterparties and our people as part of Marex.” Forward-Looking Statements: These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) and our other reports filed with the SEC. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. About Marex: Enquiries please contact: FTI Consulting US / UK
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know. Report this articleMore NewsView More
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗
Today 17:02 EDT
Via MarketBeat
Tickers
VRTX
Via MarketBeat
Tickers
VERI
Via MarketBeat
Tickers
VERA
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout ↗
Today 13:02 EDT
Via MarketBeat
Tickers
TTRX
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|

